TY - JOUR
T1 - Emerging Food Allergy Biomarkers
AU - Patil, Sarita U.
AU - Bunyavanich, Supinda
AU - Berin, M. Cecilia
N1 - Funding Information:
Conflicts of interest: S. U. Patil is supported through National Institutes of Health NIAID grant K23AI121491 . S. Bunyavanich declares no relevant conflicts of interest. M. C. Berin serves on the Scientific Advisory Board of Prota Therapeutics, and is supported by National Institutes of Health NIAID grant U19AI136053 .
Funding Information:
S. U. Patil is supported through National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) grant K23AI121491 . M. C. Berin is supported by National Institutes of Health NIAID grant U19AI136053 .
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2020/9
Y1 - 2020/9
N2 - The management of food allergy is complicated by the lack of highly predictive biomarkers for diagnosis and prediction of disease course. The measurement of food-specific IgE is a useful tool together with clinical history but is an imprecise predictor of clinical reactivity. The gold standard for diagnosis and clinical research is a double-blind placebo-controlled food challenge. Improvement in our understanding of immune mechanisms of disease, development of high-throughput technologies, and advances in bioinformatics have yielded a number of promising new biomarkers of food allergy. In this review, we will discuss advances in immunoglobulin measurements, the utility of the basophil activation test, T-cell profiling, and the use of -omic technologies (transcriptome, epigenome, microbiome, and metabolome) as biomarker tools in food allergy.
AB - The management of food allergy is complicated by the lack of highly predictive biomarkers for diagnosis and prediction of disease course. The measurement of food-specific IgE is a useful tool together with clinical history but is an imprecise predictor of clinical reactivity. The gold standard for diagnosis and clinical research is a double-blind placebo-controlled food challenge. Improvement in our understanding of immune mechanisms of disease, development of high-throughput technologies, and advances in bioinformatics have yielded a number of promising new biomarkers of food allergy. In this review, we will discuss advances in immunoglobulin measurements, the utility of the basophil activation test, T-cell profiling, and the use of -omic technologies (transcriptome, epigenome, microbiome, and metabolome) as biomarker tools in food allergy.
KW - Basophil activation test
KW - Biomarker
KW - Components
KW - Double-blind placebo-controlled food challenge (DBPCFC)
KW - Epigenome
KW - Epitopes
KW - Metabolome
KW - Microbiome
KW - T-cell receptor repertoire
KW - Transcriptome
UR - http://www.scopus.com/inward/record.url?scp=85089908561&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089908561&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.04.054
DO - 10.1016/j.jaip.2020.04.054
M3 - Article
C2 - 32888527
AN - SCOPUS:85089908561
SN - 2213-2198
VL - 8
SP - 2516
EP - 2524
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -